{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:52:09Z","timestamp":1773211929707,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.clinthera.2011.04.009","type":"journal-article","created":{"date-parts":[[2011,6,13]],"date-time":"2011-06-13T01:36:56Z","timestamp":1307929016000},"page":"443-455","source":"Crossref","is-referenced-by-count":8,"title":["Palonosetron Versus Other 5-HT3 Receptor Antagonists for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer on Chemotherapy in a Hospital Outpatient Setting"],"prefix":"10.1016","volume":"33","author":[{"given":"Sanjeev","family":"Balu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Buchner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Craver","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julie","family":"Gayle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.04.009_bib1","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/cncr.20230","article-title":"Incidence of chemotherapy-induced nausea and emesis after modern antiemetics","volume":"100","author":"Grunberg","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib2","first-page":"16","article-title":"The impact of chemotherapy-induced nausea and vomiting on the daily function and quality of life of patients","volume":"3","author":"Noonan","year":"2005","journal-title":"Adv Stud Nurs"},{"key":"10.1016\/j.clinthera.2011.04.009_bib3","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00520-006-0173-z","article-title":"Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings","volume":"15","author":"Cohen","year":"2007","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00520-007-0343-7","article-title":"A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre","volume":"16","author":"Molassiotis","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib6","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1586\/era.09.175","article-title":"Palonosetron hydrochloride for the prevention of chemotherapy-induced nausea and vomiting","volume":"10","author":"Ruhlmann","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clinthera.2011.04.009_bib7","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1093\/jnci\/83.9.613","article-title":"Serotonin antagonists: a new class of antiemetic agents","volume":"83","author":"Hesketh","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clinthera.2011.04.009_bib8","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1200\/JCO.1990.8.10.1721","article-title":"Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens","volume":"8","author":"Cubeddu","year":"1990","journal-title":"J Clin OncoI"},{"key":"10.1016\/j.clinthera.2011.04.009_bib9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(19900915)66:6<1101::AID-CNCR2820660604>3.0.CO;2-F","article-title":"Ondansetron for the prevention of emesis induced by high-dose cisplatin","volume":"66","author":"Khojasteh","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib10","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<941::AID-CNCR21>3.0.CO;2-2","article-title":"Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial","volume":"77","author":"Mantovani","year":"1996","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib11","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1053\/bbmt.2001.v7.pm11760147","article-title":"Double-blind comparative trial of oral ondansetron versus oral granisetron versus IV ondansetron in the prevention of nausea and vomiting associated with highly emetogenic preparative regimens prior to stem cell transplantation","volume":"7","author":"Fox-Geiman","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clinthera.2011.04.009_bib12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/07357900701208709","article-title":"Tropisetron, ondansetron, and granisetron for control of chemotherapy-induced emesis in Turkish cancer patients: a comparison of efficacy, side-effect profile, and cost","volume":"25","author":"Abali","year":"2007","journal-title":"Cancer Invest"},{"key":"10.1016\/j.clinthera.2011.04.009_bib13","first-page":"13","article-title":"Effects of ondansetron alone and in combination with domperidone in the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients","volume":"2","author":"Gupta","year":"2007","journal-title":"Bangladesh J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib14","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00002820-200308000-00012","article-title":"Tropisetron and dexamethasone administered twice daily for the prevention of acute emesis in patients treated with continuous infusion of cisplatin-doxorubicin and high-dose ifosfamide over 48, 24, and 120 hours","volume":"26","author":"Forni","year":"2003","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clinthera.2011.04.009_bib15","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/S0959-8049(01)00326-4","article-title":"Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis","volume":"37","author":"Tsukada","year":"2001","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib16","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra0706547","article-title":"Chemotherapy-induced nausea and vomiting","volume":"358","author":"Hesketh","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.04.009_bib17","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.11817","article-title":"Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron","volume":"98","author":"Eisenberg","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib18","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdg417","article-title":"Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron","volume":"14","author":"Gralla","year":"2003","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.clinthera.2011.04.009_bib19","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdl137","article-title":"A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy","volume":"1","author":"Aapro","year":"2006","journal-title":"Annal Oncol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1470-2045(08)70313-9","article-title":"Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomized, comparative phase III trial","volume":"10","author":"Saito","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.04.009_bib21","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.2165\/00003495-200464100-00006","article-title":"Palonosetron","volume":"64","author":"Siddiqui","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2011.04.009_bib22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1476-5381.1995.tb13283.x","article-title":"Pharmacological characterization of RS 25259-197, a novel and selective 5-HT3 receptor antagonist, in vivo","volume":"114","author":"Eglen","year":"1995","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib23","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00520-001-0335-y","article-title":"Antiemetic guidelines: creating a more practical treatment approach","volume":"10","author":"Koeller","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib26","unstructured":"Weiner MG, Livshits A, Carozzoni C, et al. Derivation of malignancy status from ICD-9 codes. American Medical Informatics Association (AMIA) 2003 Symposium Proceedings: 1050."},{"key":"10.1016\/j.clinthera.2011.04.009_bib27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"10.1016\/j.clinthera.2011.04.009_bib28","unstructured":"Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. SUGI Proceedings April 22\u201325, 2001; Long Beach Convention Center, Long Beach, California."},{"key":"10.1016\/j.clinthera.2011.04.009_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s005200100295","article-title":"Delayed emesis: incidence, pattern, prognostic factors and optimal treatment","volume":"10","author":"Roila","year":"2002","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib30","article-title":"Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3 R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis","author":"Botrel","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3111\/13696998.2010.547237","article-title":"Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States","volume":"14","author":"Craver","year":"2011","journal-title":"J Med Econ"},{"key":"10.1016\/j.clinthera.2011.04.009_bib32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00520-009-0797-x","article-title":"Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting","volume":"19","author":"Burke","year":"2010","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib33","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1002\/cncr.22823","article-title":"Costs of uncontrolled chemotherapy-induced nausea and vomiting among working-age cancer patients receiving highly or moderately emetogenic chemotherapy","volume":"110","author":"Tina Shih","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.clinthera.2011.04.009_bib34","first-page":"W9","article-title":"Identifying patients at high risk for nausea and vomiting after chemotherapy: the development of a practical validated prediction tool\u2014II","volume":"7","author":"Petrella","year":"2009","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib35","unstructured":"Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving low emetogenic chemotherapy (LEC). Presented at the 2010 International Cancer Education Conference, October 25\u201327, 2010; San Diego, California."},{"key":"10.1016\/j.clinthera.2011.04.009_bib36","doi-asserted-by":"crossref","unstructured":"Feinberg B, Gilmore J, Haislip S, et al. Likelihood of a subsequent chemotherapy induced nausea and vomiting (CINV) event in patients receiving moderately or highly emetogenic chemotherapy (MEC\/HEC). Presented at the 2010 ISPOR European Congress, November 6\u20139, 2010; Prague, Czech Republic.","DOI":"10.1016\/S1098-3015(11)71901-5"},{"key":"10.1016\/j.clinthera.2011.04.009_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ejphar.2009.10.002","article-title":"Palonosetron triggers 5-HT3 receptor internalization and causes prolonged inhibition of receptor function","volume":"626","author":"Rojas","year":"2010","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1200\/JCO.1997.15.1.116","article-title":"Determinants of postchemotherapy nausea and vomiting in patients with cancer","volume":"15","author":"Osoba","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib39","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1200\/JCO.2006.05.6382","article-title":"Delayed nausea and vomiting continue to reduce patients' quality of life after after highly and moderately emetogenic chemotherapy despite antiemetic treatment","volume":"24","author":"Bloechl-Daum","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib40","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3322\/canjclin.53.6.342","article-title":"Trends in breast cancer by race and ethnicity","volume":"53","author":"Ghafoor","year":"2003","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clinthera.2011.04.009_bib41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1097\/00002820-200503000-00004","article-title":"Racial differences in prostate cancer treatment outcomes: a systematic review","volume":"28","author":"Peters","year":"2005","journal-title":"Cancer Nurs"},{"key":"10.1016\/j.clinthera.2011.04.009_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0895-4356(00)00316-4","article-title":"Racial differences in colorectal cancer mortality","volume":"54","author":"Marcella","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clinthera.2011.04.009_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1023\/A:1022207917249","article-title":"Racial differences in lung cancer","volume":"22","author":"Gadgeel","year":"2003","journal-title":"Cancer Metastasis Rev"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811001925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,25]],"date-time":"2021-11-25T02:05:59Z","timestamp":1637805959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811001925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S0149291811001925"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.04.009","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}